Payment overview · 2025
General Payments
$790.45
41 reported records · 10 companies
Healthcare provider profile · identity verified
Shawn Wayne Coffman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTINGTON, WV · NPI 1720022643
Verified facts
What the public records show
CMS Open Payments records show Shawn Wayne Coffman, MD received $790.45 in general payments during 2025 across 41 reported records.
Paratek Pharmaceuticals, Inc. accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $315.07 | 39.9% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $174.03 | 22.0% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $89.20 | 11.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.86 | 8.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.51 | 5.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.75 | 3.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.99 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.20 | 2.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.26 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.58 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $790.45 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $315.07 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $174.03 | 14 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $89.20 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.11 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $48.44 | 3 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 249 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
32 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
53 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 747 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 562 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 513 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 511 | 148 |
| Gabapentin | Gabapentin | 499 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 489 | 124 |
| Montelukast Sodium | Montelukast Sodium | 484 | 133 |
| Omeprazole | Omeprazole | 412 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 362 | 105 |
| Furosemide | Furosemide | 315 | 88 |
| Lisinopril | Lisinopril | 282 | 80 |
| Losartan Potassium | Losartan Potassium | 258 | 69 |
| Simvastatin | Simvastatin | 254 | 63 |
| Trazodone Hcl | Trazodone Hcl | 253 | 60 |
| Eliquis | Apixaban | 249 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 244 | 56 |
| Famotidine | Famotidine | 236 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 230 | 44 |
| Tramadol Hcl | Tramadol Hcl | 218 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 210 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 64 |
| Lorazepam | Lorazepam | 202 | 39 |
| Carvedilol | Carvedilol | 192 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 38 |
| Metformin Hcl | Metformin Hcl | 187 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 56 |
| Azithromycin | Azithromycin | 179 | 122 |
| Prednisone | Prednisone | 176 | 55 |
| Diazepam | Diazepam | 164 | 31 |
| Potassium Chloride | Potassium Chloride | 164 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 162 | 108 |
| Pregabalin | Pregabalin | 162 | 35 |
| Sertraline Hcl | Sertraline Hcl | 162 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 160 | 45 |
| Irbesartan | Irbesartan | 154 | 41 |
| Methylprednisolone | Methylprednisolone | 151 | 105 |
| Clonazepam | Clonazepam | 148 | 22 |
| Valsartan | Valsartan | 139 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 135 | 100 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 17 |
| Donepezil Hcl | Donepezil Hcl | 125 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 31 |
| Celecoxib | Celecoxib | 123 | 34 |
| Xarelto | Rivaroxaban | 122 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 117 | 37 |
| Benazepril Hcl | Benazepril Hcl | 110 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 39 |
| Meloxicam | Meloxicam | 105 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 22 |
| Glimepiride | Glimepiride | 103 | 33 |
| Ibuprofen | Ibuprofen | 93 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 27 |
| Allopurinol | Allopurinol | 90 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 62 |
| Cefdinir | Cefdinir | 84 | 52 |
| Synthroid | Levothyroxine Sodium | 84 | 27 |
| Mirtazapine | Mirtazapine | 83 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 81 | 27 |
| Torsemide | Torsemide | 81 | 22 |
| Ezetimibe | Ezetimibe | 80 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 21 |
| Bupropion Hcl | Bupropion Hcl | 76 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 23 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 75 | 19 |
| Finasteride | Finasteride | 75 | 22 |
| Methylphenidate Er | Methylphenidate Hcl | 74 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | 16 |
| Estradiol | Estradiol | 69 | 17 |
| Jardiance | Empagliflozin | 69 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 15 |
| Temazepam | Temazepam | 69 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 69 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 20 |
| Zaleplon | Zaleplon | 67 | 16 |
| Testosterone | Testosterone | 66 | 13 |
| Metformin Hcl Er | Metformin Hcl | 65 | 22 |
| Warfarin Sodium | Warfarin Sodium | 65 | 18 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 19 |
| Ozempic | Semaglutide | 60 | 16 |
| Bupropion Xl | Bupropion Hcl | 59 | 23 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 59 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 18 |
| Sotalol | Sotalol Hcl | 56 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 24 |
| Levofloxacin | Levofloxacin | 54 | 41 |
| Paxlovid | Nirmatrelvir/Ritonavir | 53 | 49 |
| Spironolactone | Spironolactone | 53 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Trulicity | Dulaglutide | 50 | suppressed |
| Atenolol | Atenolol | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 49 | 13 |
| Ketoconazole | Ketoconazole | 48 | 20 |
| Lidocaine | Lidocaine | 48 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 14 |
| Tradjenta | Linagliptin | 48 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 15 |
| Fluconazole | Fluconazole | 46 | 34 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 46 | 16 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 12 |
| Lansoprazole | Lansoprazole | 43 | 11 |
| Hydrocortisone | Hydrocortisone | 41 | 16 |
| Methotrexate | Methotrexate Sodium | 41 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 16 |
| Ondansetron Odt | Ondansetron | 38 | 17 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Linzess | Linaclotide | 35 | 12 |
| Naproxen | Naproxen | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 15 |
| Metolazone | Metolazone | 34 | 13 |
| Propranolol Hcl | Propranolol Hcl | 34 | 11 |
| Topiramate | Topiramate | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 24 |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Nystatin | Nystatin | 31 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Flurbiprofen | Flurbiprofen | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | 19 |
| Rybelsus | Semaglutide | 30 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Nabumetone | Nabumetone | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Metronidazole | Metronidazole | 28 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Clarithromycin | Clarithromycin | 17 | 14 |
| Etodolac | Etodolac | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Nexletol | Bempedoic Acid | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Salsalate | Salsalate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $790.45 · 41 records | Paratek Pharmaceuticals, Inc. | ELIQUIS, FUROSCIX, JYNARQUE, LEQVIO, MOUNJARO, NUZYRA, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XHANCE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error